Exploring the venomous potential of marine crustaceans for drug development

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it

Car­diore­nal biotech Renibus Ther­a­peu­tics has com­plet­ed a Se­ries B ex­ten­sion that brings its to­tal pro­ceeds to $72 mil­lion, se­cur­ing a run­way through reg­is­tra­tional de­vel­op­ment and